

Meningitis


**Supplier meeting
UNICEF Supply Division 3-4 April 2008**

Katinka Rosenbom

Meningitis


Meningitis vaccine AC and ACW135	
Demand Profile	
Presentation	10 & 50 dose vials
Quantity	N/A
Activity Split: Routine, Campaign	Vaccine used for outbreak response due to short life immunity
Demand Volatility: Urgency of Need, Reliability of Demand	Outbreak driven demand, mainly of type A. Extremely tight supply situation. Demand closely monitored by the ICG for African belt during the outbreak seasons.
Anticipated duration of Demand	PS vaccine continued to be used for outbreak response. Continued demand through 2014 if improved funding situation.
Trends	Funding availability has constrained demand. Large ad hoc demand has not been met by supply
Market Profile	
Development Stage	Very Fragile market - one manufacturer recently entered the market. No additional expected
Market Status	3 WHO pre-qualified
Trends	Slight improvement with 3 suppliers.
Vaccine Security Status	
Forecast Accuracy	Very low from both supply and demand perspective
Funding Profile	Lack of funding has been one of the major difficulties in meeting the need. If new GAVI IC is approved the situation will be much improved
Contracting	Differing arrangements due to limited vaccine availability, specific solutions to accomodate outbreak response preparedness
Supply Status	Very constrained supply situation

Meningitis AC - Proc overview - Future



- Historically limited funding and supply. Only 1 manufacturer for many years.
- UNICEF has only procured a part of the outbreak supply.
- Demand > supply. Supply has been reserved for outbreak response
- Future demand will depend on funding and vaccine availability. If both become available the Mening AC demand is projected to be around 6 million dose per year through GAVI partners.
- Country funded demand (direct or through UNICEF) would be in addition.

Meningitis – Funding (US\$ Value)



- The different funding sources, country situation and outbreak specific is evident here.
- UNICEF has not had a formal role in outbreak supply, but supported with appropriate and possible
- The lack of funding and constrained supply situation has also made the forecasting inaccurate

Meningitis Polysaccharide vaccines 2007-08

Mening AC:

Not used in preventive strategy – only used for outbreak pre-positioning and response

Extremely limited market

- Only 1 supplier in 2007, 2nd pre-qualified end 2007
- Demand is unpredictable
- Supply has been reserved for outbreak response and access been guided by the ICG for Meningitis

2007 Two mechanism for response:

- Outbreak (through ICG approval)
- Pre-Positioning (WHO recommended list)
- Total delivery through UNICEF 1.7 mds,
- Global demand/distribution through ICG partners 6.97 mds

Meningitis ACW:

- Stand by quantity of 1.5 Mds since 2004, intended for confirmed W 135 outbreaks only.
- No delivery through UNICEF yet, 1 MDS delivered through ICG in 2007
- Confirmed W135 outbreaks have been lower than anticipated since the establishment of the quantity.

Meningitis 2008 and beyond

2008 (PS AC) outbreak season

- 2 WHO pre-qualified suppliers as of early 2008
- 3.14 Mds delivered through UNICEF as of today
- Additional request in process

Future Meningitis vaccine demand;

- Investment case to be submitted to GAVI for conjugate meningitis A vaccine support
- Recommends a multi faceted strategy combining;
 - reinforced outbreak response capacity with polysaccharide vaccines (through 2014),
 - catch-up campaigns with conjugate A vaccines providing longer lasting immunity, and
 - potential introduction in EPI schedule of conjugate A vaccines if infant protection is proved.
- UNICEF SD is likely to be involved in the procurement should the investment case be funded, and will tender Q3 2008 should this become reality.

Thank You